Incyte | INCY - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agenus USD -221.22M 241.03M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Exelixis USD 359.47M 3.28M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 9.29B 507M 2026-03
Novartis USD 9.8B 23M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03